Načítá se...
ALK and NSCLC: Targeted therapy with ALK inhibitors
For many years treatment for advanced or metastatic non-small cell lung cancer (NSCLC) has employed chemotherapy regimens for patient care, with limited effect. Five-year survival rates for these patients are not encouraging. However, for a subgroup of these patients, there have been radical changes...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Faculty of 1000 Ltd
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3206708/ https://ncbi.nlm.nih.gov/pubmed/22076124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3410/M3-21 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|